ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 245

Improvement in Fibromyalgia Symptoms and Skin Biopsy Results in Patients with Fibromyalgia and Small Fiber Neuropathy Treated with Intravenous Immune Globulin Infusion( IVIG)

Samy Metyas1,2, Haidy Youssef3, Christina Chen2, Anne Quismorio2 and Jennifer Bui2, 1Rheumatology, Clinical Associate Professor of Rheumatology at USC, Los Angeles, CA, 2Rheumatology, Covina Arthritis Clinic, Covina, CA, 3internal medicine, Riverside community hospital/ UCR school of medicine, riverside, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: fibromyalgia, intravenous immunoglobulin (IVIG) and small fiber neuropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Fibromyalgia and Other Clinical Pain Syndromes Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Small fiber neuropathy is often a challenging clinical problem; patients with small fiber sensory neuropathy commonly have severe complaints but only minimal objective abnormalities on examination. Because it affects mainly small, unmyelinated nerve fibers, standard electrophysiological testing is often normal, and skin biopsy was proven to be diagnostic with sensitivity in 88% of cases in one study. The purpose of this study is to assess the effectiveness of IVIG in the treatment of SFN in patients with Fibromyalgia both subjectively (patient reported improvement in symptoms) and objectively by measuring nerve fiber density through skin biopsy before and after 6 months of treatment.

Methods: Our study is an interventional open labelled treatment trial, involving 7 patients diagnosed with Fibromylagia according to ACR criteria and had symptoms of SFN (ranging from chronic extremity pain, numbness or tingling)

All the 7 patients were diagnosed by Small fiber neuropathy after undergoing a 3 mm punch skin biopsy (1 on the thigh and one on the lower leg, as approved by the American Academy of Neurology) and the decrease in nerve fiber density was used for diagnosis of SFN)

All patients after being diagnosed with SFN on skin biopsy got 6 months of weight based IVIG treatment (2gm/kg).

Objective effectiveness of IVIG therapy was assessed by a repeat post treatment biopsy after completing the 6 months of treatment.

Subjective effectiveness was assessed by patient-filled FIQR questionnaires before and after treatment.

Patient demographics:

Age groups

42-68

Male: Female ratio

1:6

Prevalence of Fibromyalgia

7 of 7 patients

100%

Prevalence of Rheumatoid

3 of 7 patients

42.86%

Prevalence of Sjogren’s disease

4 of 7 patients

57.14%

Prevalence of Sarcoidosis

1 of 7 patients

14.29%

Prevalence of vitamin D deficiency

3 of 7 patients

42.86%

Results:

Revised Fibromyalgia Impact Questionnaire ( FIQR) results before and after treatment:

Patient

FIQR score before treatment

FIQR score after treatment

Magnitude of improvement change

1

85

27

58

2

70

48

22

3

27

0

27

4

64

41

23

5

83

58

25

6

23.6

9.3

14.3

7

78

71

7

Nerve fiber diameter on skin Biopsy before and after treatment:

Pt

Pretreatment upper thigh nerve fiber diameter

Post-treatment upper thigh nerve fiber diameter

Magnitude of change in upper thigh nerve diameter

Pretreatment lower leg nerve fiber diameter

Post-treatment lower leg nerve fiber diameter

Magnitude of change in lower leg nerve diameter

Net change of nerve fiber diameter

1

3.9 mm

9.3 mm

+5.4 mm

5.3 mm

12.4 mm

+7.1 mm

+12.5 mm

2

5.0 mm

3.5 mm

-1.5 mm

0.4 mm

1.6 mm

+1.2 mm

-0.3 mm

3

3.6 mm

11 mm

+7.4 mm

0.4 mm

0.8 mm

+0.4 mm

+7.8 mm

4

4.3 mm

9.5 mm

+5.2 mm

0.3 mm

0.0 mm

-0.3 mm

+4.9 mm

5

2.6 mm

4.9 mm

+2.3 mm

1.2 mm

6.8 mm

+5.6 mm

+7.9 mm

6

4.6 mm

9.9 mm

+5.3 mm

5.5 mm

4.3 mm

-1.2 mm

+4.1 mm

7

3.0 mm

3.6 mm

+0.6 mm

1.5 mm

4.5 mm

+3 mm

+3.6 mm

Mean improvement changes of FIQR score is 25, mean improvement of upper thigh nerve diameter is 3.5 mm, and mean improvement of lower leg nerve diameter is 5.7 mm.

Conclusion:

As shown in our study, IVIG has been proven to be very effective in improving SFN on both the clinical and the pathophysiologic levels and should be considered for the routine management of this underdiagnosed, yet very troublesome and crippling disease. Larger scale studies are definitely needed to confirm these results and facilitate the wider use of IVIG in treatment.


Disclosure: S. Metyas, None; H. Youssef, None; C. Chen, None; A. Quismorio, None; J. Bui, None.

To cite this abstract in AMA style:

Metyas S, Youssef H, Chen C, Quismorio A, Bui J. Improvement in Fibromyalgia Symptoms and Skin Biopsy Results in Patients with Fibromyalgia and Small Fiber Neuropathy Treated with Intravenous Immune Globulin Infusion( IVIG) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/improvement-in-fibromyalgia-symptoms-and-skin-biopsy-results-in-patients-with-fibromyalgia-and-small-fiber-neuropathy-treated-with-intravenous-immune-globulin-infusion-ivig/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-in-fibromyalgia-symptoms-and-skin-biopsy-results-in-patients-with-fibromyalgia-and-small-fiber-neuropathy-treated-with-intravenous-immune-globulin-infusion-ivig/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology